Clinical Activity After 12 Weeks of Treatment with Nonbiologics in Early Rheumatoid Arthritis May Predict Articular Destruction 2 Years Later

Abstract

In patients with early RA, ACR core set measures after 12 weeks of nonbiologic DMARD treatment may predict articular destruction 2 years later. Low response to treatment at 12 weeks and continuing high disease activity thereafter were found in patients with rapid radiological progression. These data can be used to determine the appropriateness of treatment at 12 weeks and aid the decision to introduce biologic DMARD.

Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial

“…Importantly, the addition of CZP to MTX inhibited radiographic progression in both the 12-week responder and nonresponder groups when compared with placebo. These results support the recent findings of Ichikawa, et al 25 , who found that in patients with early RA, ACR core set measures after 12 weeks of nonbiologic DMARD treatment predicted articular destruction 2 years later, demonstrating the importance of obtaining rapid control of disease activity in order to prevent longterm irreversible damage. Similarly, Smolen, et al demonstrated that attainment of remission or LDA at 3 months led to no or minimal progression of joint damage over a 1-year period in patients treated with MTX + infliximab 26 .…”

Use of Subcutaneous Methotrexate for the Treatment of Patients With Active Rheumatoid Arthritis: The Remarca Trial

“…Это соответствует материалам исследований других авторов, в которых было показано, что развитие ремиссии в течение первых 8-12 нед на фоне монотерапии МТ позволяет предсказать сохранение ремиссии через год. В то же время отсутствие ремиссии через 4-6 мес на фоне комбинированной терапии МТ и ГИБП ассоциируется с резистентностью к этой комбинации и свидетельствует о необходимости смены ГИБП [32][33][34][35][36][37].…”

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis

“…[1][2][3][4][5] To our knowledge, this approach has not been utilized in patients with psoriasis receiving biologic therapies. Early improvements in disease activity have been associated with improved long-term clinical outcomes in psoriasis patients treated with methotrexate, as well as patients with other autoimmune diseases.…”

“…Currently, there are no objective criteria for predicting responsiveness to biologic treatment for psoriasis. Early improvements in disease activity have been associated with improved long‐term clinical outcomes in psoriasis patients treated with methotrexate, as well as patients with other autoimmune diseases . To our knowledge, this approach has not been utilized in patients with psoriasis receiving biologic therapies.…”